September 17, 2018
A nationwide survey conducted by Wedgewood Pharmacy aims to show the unintended consequences for veterinary medicine caused by the Drug Enforcement Administration’s (DEA) efforts to address the national opioid crisis.
To address the misuse and diversion of opioids by people, the DEA has proposed an average 10 percent decrease in the 2019 manufacturing quotas for six frequently abused opioids, including five key Class II opioid drugs commonly used by veterinarians.
When supplies of these drugs are limited, manufacturers and distributors give preference to allocating supplies for use in human health, creating shortages for veterinary medical practitioners, Wedgewood said in a statement.
The results will be included in formal comments the company will submit to the DEA regarding the proposed production quota reductions.
“Shortages limit therapeutic choices and are especially problematic given the number of species veterinarians treat—from tiny kittens to large dogs, horses, and even elephants—and how different species react to opioids or their alternatives,” said Michael Blaire, RPh, FIACP, vice president, Government and Regulatory Affairs for Wedgewood. “Shortages demand that veterinarians frequently change medications and pain-management protocols, and this increases the risk of medical errors. While we applaud DEA’s efforts to address the national opioid crisis among humans, we’re asking them to be thoughtful about the impact the actions they take will have on the animal patients owned by 68 percent of American homes and the millions of animals in zoos, aquaria, stables, shelters, hospitals, research facilities, police, and military facilities. We need to work together to address a national crisis in human health while continuing to provide veterinarians with the medicines they need to practice.”
Source URL: https://www.veterinarypracticenews.com/survey-highlights-impact-opioid-shortages-veterinary-medicine/
Copyright ©2020 Veterinary Practice News unless otherwise noted.